- News Library
- Servier Medical Art
- Partnering & Licensing
Transparency Policy on Clinical Trial Data
One of Servier's guiding principles is that our research should make a significant contribution to medical progress. This principle drives our commitment to data-sharing initiatives, which we believe is an important way forward in clinical research to enhance global public health.
With research programs ongoing in 6 major fields of medicine, Servier stands as a major player in pharmaceutical research. Collaboration between industry and external medical and scientific research partners is essential to progress in clinical research and drug development. This collaboration can only be successful if it is transparent, responsible, and fully compliant with regulatory requirements, and if it completely respects patient rights.
At Servier, we are dedicated to the proper conduct of clinical trials, with initiatives extending to cover the most recent regulations. Servier adheres to the Principles for Responsible Clinical Trial Data-Sharing laid out by the EFPIA (European Federation of Pharmaceutical Industries and Associations) and PhRMA (Pharmaceutical Research and Manufacturers of America). This includes the timely registration of clinical trial protocols, communication and publication of results from our clinical research programs, and sharing results with the patients who participate in our clinical trials. Servier makes clinical trial data and anonymized patient data available to qualified scientific and medical researchers, in accordance with international statutory requirements regarding the disclosure of clinical studies.